The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer.
Narrative review focussing on PSMA as a target for RLT, and data using
RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate‐resistant prostate cancer (mCRPC). To date, most evidence exists regarding small‐molecule PSMA inhibitors bound to beta‐emitting radioisotopes such as 177Lu (Lu‐PSMA). Prospective phase II data supports the safety and efficacy of Lu‐PSMA in men with heavily pre‐treated progressive mCRPC, and several late‐phase randomised trials of Lu‐PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states.
PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer.
Narrative review focussing on PSMA as a target for RLT, and data using
RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate‐resistant prostate cancer (mCRPC). To date, most evidence exists regarding small‐molecule PSMA inhibitors bound to beta‐emitting radioisotopes such as 177Lu (Lu‐PSMA). Prospective phase II data supports the safety and efficacy of Lu‐PSMA in men with heavily pre‐treated progressive mCRPC, and several late‐phase randomised trials of Lu‐PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states.
PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
To review current data for the role of prostate specific membrane antigen (PSMA) radioligand therapy (RLT) for patients with advanced prostate cancer. This review provides an update for multidisciplinary teams on the current and potential future applications of theranostics in prostate cancer.
Narrative review focussing on PSMA as a target for RLT, and data using
RLT with PSMA is an exciting therapeutic alternative to the existing management options already in use for patients with metastatic castrate‐resistant prostate cancer (mCRPC). To date, most evidence exists regarding small‐molecule PSMA inhibitors bound to beta‐emitting radioisotopes such as 177Lu (Lu‐PSMA). Prospective phase II data supports the safety and efficacy of Lu‐PSMA in men with heavily pre‐treated progressive mCRPC, and several late‐phase randomised trials of Lu‐PSMA are underway, with many more in the pipeline. Early results are encouraging, indicating that the theranostic approach may play a vital role in management of advanced prostate cancer and perhaps even in much earlier disease states.
PSMA RLT is a promising new treatment option for men with mCPRC, and may also have utility in less advanced prostate cancer.
The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.
[#feed_custom_content:encoded]
The management of symptomatic BPH is evolving and there is now an expanding portfolio of minimally invasive surgical therapies (MIST). These provide an attractive option for men looking for meaningful improvement in urinary symptoms whilst avoiding the risks of adverse effects, particularly with regards to maintaining sexual function.